Cutaneous T-cell lymphoma · 3 regimens
Cost vs Efficacy · 3 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Busulfan and Fludarabine, then allo HSCT Variant #08 Partial | — | R 30 308 | — | 9.0 mo | — | 1 | R 30 308 PFS proxy | 1 |
Fludarabine and Melphalan, then allo HSCT Variant #02 Partial | — | — | — | 9.0 mo | — | 1 | — | 1 |
Busulfan, Fludarabine, Thiotepa, then allo HSCT Variant #01 Partial | — | — | — | 9.0 mo | — | 1 | — | 1 |
3 of 3 regimens shown